

*Going beyond Commitment,*



## SUVEN LIFE SCIENCES LTD

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110TG1989PLC009713

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: investorservices@suvan.com website: www.suvan.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31 Dec' 2015

**PART - I**

Sl. No.	PARTICULARS	For the Quarter Ended			Nine months ended		Rs. in Lacs
		31/12/2015	30/09/2015	31/12/2014	31/12/2015	31/12/2014	Previous Year Ended
		Un-Audited	un-Audited	Un-Audited	un-Audited	un-Audited	Audited
1	<b>Income from operations</b>						
	(a) Net sales/income from operations (Net of excise duty)	11,250.43	11,676.14	12,882.97	33,024.71	41,019.25	52,085.50
	(b) Other operating income	-	-	-	-	-	-
	<b>Total income from operations (net)</b>	<b>11,250.43</b>	<b>11,676.14</b>	<b>12,882.97</b>	<b>33,024.71</b>	<b>41,019.25</b>	<b>52,085.50</b>
2	<b>Expenses</b>						
	a) Cost of materials consumed	4,180.63	5,131.75	4,413.80	13,181.02	13,177.17	17,724.78
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(413.63)	(1,692.51)	(1,020.96)	(3,130.29)	1,009.23	347.95
	d) Employee benefits expense	1,158.02	1,107.57	963.42	3,219.81	2,655.98	3,651.16
	e) Depreciation and amortisation expense	451.96	449.80	290.82	1,192.22	910.58	1,177.58
	f) Other expenses - Manufacturing Exps	1,799.32	1,921.74	1,812.03	5,283.51	4,804.49	6,444.21
	- R & D Exps	1,516.96	1,506.29	1,469.96	4,616.85	4,058.80	5,596.26
	- Others	545.58	628.02	602.51	1,813.07	1,639.47	2,375.29
	<b>Total expenses</b>	<b>9,238.84</b>	<b>9,052.66</b>	<b>8,531.58</b>	<b>26,176.19</b>	<b>28,255.72</b>	<b>37,317.23</b>
3	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>2,011.59</b>	<b>2,623.48</b>	<b>4,351.39</b>	<b>6,848.52</b>	<b>12,763.53</b>	<b>14,768.27</b>
4	<b>Other Income</b>	<b>397.00</b>	<b>578.73</b>	<b>227.13</b>	<b>1,483.27</b>	<b>477.05</b>	<b>858.12</b>
5	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)</b>	<b>2,408.59</b>	<b>3,202.21</b>	<b>4,578.52</b>	<b>8,331.79</b>	<b>13,240.58</b>	<b>15,626.39</b>
6	<b>Finance costs</b>	<b>153.86</b>	<b>139.52</b>	<b>100.55</b>	<b>385.62</b>	<b>349.96</b>	<b>470.92</b>
7	<b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)</b>	<b>2,254.73</b>	<b>3,062.69</b>	<b>4,477.97</b>	<b>7,946.17</b>	<b>12,890.62</b>	<b>15,155.47</b>
8	<b>Exceptional Items</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
9	<b>Profit/Loss from Ordinary Activities before tax (7 ± 8)</b>	<b>2,254.73</b>	<b>3,062.69</b>	<b>4,477.97</b>	<b>7,946.17</b>	<b>12,890.62</b>	<b>15,155.47</b>
10	<b>Tax Expenses</b>	<b>482.80</b>	<b>589.83</b>	<b>1,255.31</b>	<b>1,678.31</b>	<b>3,710.49</b>	<b>4,280.44</b>
11	<b>Net Profit/ (Loss) from Ordinary Activities after tax (9 ± 10)</b>	<b>1,771.93</b>	<b>2,472.86</b>	<b>3,222.66</b>	<b>6,267.86</b>	<b>9,180.13</b>	<b>10,875.03</b>
12	<b>Extraordinary Items (net of tax expense ₹ ____ Lakhs)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
13	<b>Net Profit (+)/Loss(-) for the period (11 ± 12)</b>	<b>1,771.93</b>	<b>2,472.86</b>	<b>3,222.66</b>	<b>6,267.86</b>	<b>9,180.13</b>	<b>10,875.03</b>
14	<b>Share of profit / (loss) of associates*</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
15	<b>Minority interest *</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
16	<b>Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 ± 14 ± 15) *</b>	<b>1,771.93</b>	<b>2,472.86</b>	<b>3,222.66</b>	<b>6,267.86</b>	<b>9,180.13</b>	<b>10,875.03</b>
17	<b>Paid-up equity share capital</b> (Face Value of the Share shall be indicated)	<b>1,272.82</b> <b>Re.1.00</b>	<b>1,272.82</b> <b>Re.1.00</b>	<b>1,272.82</b> <b>Re.1.00</b>	<b>1,272.82</b> <b>Re.1.00</b>	<b>1,272.82</b> <b>Re.1.00</b>	<b>1,272.82</b> <b>Re.1.00</b>
18	<b>Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year</b>						54,658.58
19.i	<b>Earning Per Share (EPS) (before extraordinary items) (of ₹ Rs.1/- each) (not annualised):</b>						
	a) Basic	1.39	1.94	2.73	4.92	7.78	9.04
	b) Diluted	1.39	1.94	2.73	4.92	7.78	9.04
19.ii	<b>Earning Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):</b>						
	a) Basic	1.39	1.94	2.73	4.92	7.78	9.04
	b) Diluted	1.39	1.94	2.73	4.92	7.78	9.04

PART - II								
A	PARTICULARS OF SHAREHOLDING	31/12/2015	30/09/2015	31/12/2014	31/12/2015	31/12/2014	31/3/2015	
		Un-Audited	un-Audited	Un-Audited	un-Audited	un-Audited	Audited	
1	Public share holdings							
	- Number of shares	51,462,478	51,462,478	51,624,902	51,462,478	51,624,902	51,624,902	
	- Percentage of Share holding	40.43%	40.43%	40.56%	40.43%	40.56%	40.56%	
2	Promoters and promoter group Shareholding**							
a)	Pledged / Encumbered	NIL	NIL	NIL	NIL	NIL	NIL	
	- Number of shares							
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL	
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL	NIL	
b)	Non-Encumbered	75,820,000	75,820,000	75,657,576	75,820,000	75,657,576	75,657,576	
	- Number of shares							
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	
	- Percentage of shares (as a % of the total share capital of the company)	59.57%	59.57%	59.44%	59.57%	59.44%	59.44%	
	Particulars	31/12/2015						
B	INVESTOR COMPLAINTS							
	Pending at the beginning of the quarter	0						
	Received during the quarter	46						
	Disposed of during the quarter	46						
	Remaining unresolved at the end of the quarter	0						

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED							Rs.in Lacs
PARTICULARS	Quarter Ended			Nine Months ended		Year Ended	
	31/12/2015	30/09/2015	31/12/2014	31/12/2015	31/12/2014	31/3/2015	
	Un-Audited	un-Audited	Un-Audited	un-Audited	un-Audited	Audited	
1	SEGMENT REVENUE :-						
a)	Manufacturing (CRAMS)	10,252.62	10,475.82	12,328.69	30,299.98	39,230.28	
b)	Services (DDDSS)	997.81	1,200.32	554.28	2,724.73	1,788.97	
c)	Research & Development	-	-	-	-	-	
	Net Sales from Operations	11,250.43	11,676.14	12,882.97	33,024.71	41,019.25	
2	SEGMENT RESULTS :-						
	Profit/(Loss) before tax and interest:						
a)	Manufacturing (CRAMS)	3,310.74	3,770.24	6,137.28	11,131.39	17,169.08	
b)	Services (DDDSS)	622.30	813.15	174.33	1,669.62	947.17	
c)	Research & Development	(1,516.97)	(1,506.27)	(1,469.96)	(4,616.85)	(4,058.80)	
	TOTAL	2,416.07	3,077.12	4,841.65	8,184.16	14,057.45	
Less:	i) Interest	107.66	101.90	65.34	262.52	224.77	
	ii) Other Un-allocable exps net off un-allocable Income	53.68	(87.47)	298.34	(24.53)	942.06	
	Total Profit Before Tax	2,254.73	3,062.69	4,477.97	7,946.17	12,890.62	
3	CAPITAL EMPLOYED						
	(Segment Assets - Segment Liabilities)						
a)	Manufacturing (CRAMS)	40,455.95	36,350.56	30,723.12	40,455.95	30,723.12	
b)	Services (DDDSS)	3,314.19	3,460.06	3,170.05	3,314.19	3,170.05	
c)	Research & Development	239.23	351.84	841.37	239.23	841.37	
d)	Un allocated	27,167.79	28,872.23	29,106.35	27,167.79	29,106.35	
	TOTAL	71,177.16	69,034.69	63,840.89	71,177.16	63,840.89	

Notes: 1) The above results were reviewed by Audit committee and approved by the Board of Directors' meeting held on 12 th Feb'16  
2) Corresponding Previous period figures have been regrouped / reclassified whenever necessary.  
3) The above results were reviewed by Auditors .

For SUVEN LIFE SCIENCES LTD

VENKAT JASTI  
Chairman & CEO  
DIN: 00278028

Place : Hyderabad  
Date : 12 th Feb ' 2016

*We Deliver*